We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2022

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Executive Summary

The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.

The report titled "Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2022" also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.

Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments

The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017- 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine. The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.

Scope of the Report

Migraine Pipeline Drugs Assessment - Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)
- Market Potential
- Clinical Trials
- Product Description
- Regulatory Phases
- 7Ps Analysis

Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Market Sizing and Growth
- Market Sizing and Growth By Type - Acute and Prophylaxis

Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Market Sizing and Growth

Other Report Highlights
- Market Dynamics - Drivers, Challenges
- Company Analysis - Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline

Customization of the Report

The report could be customized according to the client s specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Migraine - An Overview
3.1. Symptoms of migraine
3.2. Stages of Migraine
3.3.Types of Migraine
3.4. Types of migraine on the basis of frequency of occurrence

4. Treatment of Migraine
4.1. Goal of Migraine Treatment
4.2. Treatment of Migraine - Pharmacological and Non-Pharmacological
4.2.1. Pharmacological treatment of migraine
4.2.2. Pharmacological - Abortive
4.2.3. Pharmacological - Preventive
4.2.4. Non-Pharmacological Treatment of Migraine
4.2.5. Non- Pharmacological - Surgical
4.2.6. Non- Pharmacological - Non-Surgical

5. Anti-Migraine Pipeline Drugs Analysis

5.1. Anti-Migraine Pipeline Drugs (According to Mechanism of Working)

5.2. Anti-Migraine Pipeline Drugs (Ergotamine): Drug - X1
5.2.1. Description
5.2.2. Regulatory Milestones
5.2.3. Advantages & Disadvantages
5.2.4. Product Profile & Expected Launch
5.2.5. Clinical Trials and Status
5.2.6. Pivotal Clinical Trials and Results
5.2.7. Drug X-1- Global Market Potential
5.2.8. Drug X-1- 7Ps Analysis

5.3. Anti-Migraine Pipeline Drugs (Anti-5HT Receptor Agonist): Drug - X2
5.3.1. Description
5.3.2. Regulatory Milestones
5.3.3. Advantages & Disadvantages
5.3.4. Product Profile & Expected Launch
5.3.5. Clinical Trials and Status
5.3.6. Pivotal Clinical Trials and Results
5.3.7. Drug - X2 - Global Market Potential
5.3.8. Drug - X2 - 7Ps Analysis

5.4. Anti-Migraine Pipeline Drugs (Anti CGRPs) 

5.5. Anti-Migraine Pipeline Drugs (Anti CGRPs) - By Drug

5.6. Anti-Migraine Pipeline Drugs (CGRP Antagonist): Drug - X3
5.6.1. Description
5.6.2. Regulatory Milestones
5.6.3. Advantages & Disadvantages
5.6.4. Product Profile & Expected Launch
5.6.5. Clinical Trials and Status
5.6.6. Pivotal Clinical Trials and Results
5.6.7. Drug - X3 - Global Market Potential
5.6.8. Drug - X3 - 7Ps Analysis

5.7. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X4
5.7.1. Description
5.7.2. Regulatory Milestones
5.7.3. Advantages & Disadvantages
5.7.4. Product Profile & Expected Launch
5.7.5. Clinical Trials and Status
5.7.6. Pivotal Clinical Trials and Results
5.7.7. Drug - X4 - Global Market Potential
5.7.8. Drug - X4 - 7Ps Analysis

5.8. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X5
5.8.1. Description
5.8.2. Regulatory Milestones
5.8.3. Advantages & Disadvantages
5.8.4. Product Profile & Expected Launch
5.8.5. Clinical Trials and Status
5.8.6. Pivotal Clinical Trials and Results
5.8.7. Drug - X5 - Global Market Potential
5.8.8. Drug - X5 - 7Ps Analysis

5.9. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X6
5.9.1. Description
5.9.2. Regulatory Milestones
5.9.3. Advantages & Disadvantages
5.9.4. Product Profile & Expected Launch
5.9.5. Clinical Trials and Status
5.9.6. Pivotal Clinical Trials and Results
5.9.7. Drug - X6 - Global Market Potential
5.9.8. Drug - X6 - 7Ps Analysis

5.10. Anti-Migraine Pipeline Drugs (Anti-CGRP Mab): Drug - X7
5.10.1. Description
5.10.2. Regulatory Milestones
5.10.3. Advantages & Disadvantages
5.10.4. Product Profile & Expected Launch
5.10.5. Clinical Trials and Status
5.10.6. Pivotal Clinical Trials and Results
5.10.7. Drug - X7 - Global Market Potential
5.10.8. Drug - X7 - 7Ps Analysis

6. Global Migraine Drugs Market: Growth and Forecast
6.1. By Value (2012-2016)
6.2. By Value (2017-2022)

7. Global Migraine Drugs Market - Analysis By Type
7.1. Global Migraine Drugs Market, By Type: Breakdown (%)
7.1.1. Global Migraine Drugs Market- By Type: 2016 (%)
7.1.2. Global Migraine Drugs Market   By Type: 2022 (%)
7.2. Global Migraine Drugs Market- By Acute
7.2.1. By Value (2012-2016)
7.2.2. By Value (2017-2022)
7.3. Global Migraine Drugs Market- By Prophylaxis
7.3.1. By Value (2012-2016)
7.3.2. By Value (2017-2022)

8. Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW)                                                                                         
8.1. U.S. Migraine Drugs Market, By Value (2012-2022)
8.2. U.K. Migraine Drugs Market, By Value (2012-2022)
8.3. Japan Migraine Drugs Market, By Value (2012-2022)
8.4. France Migraine Drugs Market, By Value (2012-2022)
8.5. Italy Migraine Drugs Market, By Value (2012-2022)
8.6. Germany Migraine Drugs Market, By Value (2012-2022)
8.7. ROW Migraine Drugs Market, By Value (2012-2022)

9. Market Dynamics
9.1. Migraine Drug Market Drivers
9.2. Migraine Drug Market Challenges

10. Company Profiles
10.1. Amgen
10.2. Allergan
10.3. Eli Lilly
10.4. Alder Pharmaceuticals
10.5. Teva Pharmaceuticals
10.6. Vernalis
10.7. Pfizer
10.8. Impax Laboratories
10.9. Glaxo Smithkline

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved